The Top Line cover image

Misconduct and the future of neurodegenerative disease research

The Top Line

00:00

Critical Examination of Antibody Treatments for Neurodegenerative Diseases

This chapter examines Prathena Biosciences' prazinezumab, an antibody treatment for Parkinson's disease, focusing on its trial history and the challenges faced, including previous trials yielding results indistinguishable from placebo. The chapter highlights concerns over the validity of the treatment and discusses the recommendation to halt ongoing research based on a thorough analysis of trial data.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app